Meta-analysis of safety and efficacy of rolapitant, NK-1 receptor antagonist for prevention of chemotherapy induced nausea and vomiting ☆☆

Although chemotherapeutic agents represent a cornerstone of cancer treatment, chemotherapy-induced nausea and vomiting (CINV) is one of the most disturbing hazards of cytotoxic therapy that affects the patients ‘ quality of life and basic daily activities. Rolapitant is a novel selective neurokinin-1 receptor antagonist (NK-1 RA), which was clinically approved for prevention of CINV. The aim of the present study is to synthesize evidence about the safety and efficacy of rolapitant in combination with ot her antiemetic agents for prophylaxis against CINV.
Source: Current Problems in Cancer - Category: Cancer & Oncology Authors: Source Type: research